Source:http://linkedlifedata.com/resource/pubmed/id/19762336
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
11
|
pubmed:dateCreated |
2009-11-26
|
pubmed:abstractText |
Murine double minute 4 (MDM4) shares significant structural homology with murine double minute 2 (MDM2) and interacts and regulates transcriptional activity of the tumor suppressor p53. In tumors with wild-type p53, there is often overexpression of MDM2 or MDM4 leading to functional inactivation of p53. A single-nucleotide polymorphism (SNP) in the promoter of human MDM2 (SNP309) was shown to associate with increased MDM2 expression and increased risk of cancer. This study evaluated the association of a SNP in human MDM4 (C>T) with age of onset of breast cancer in two independent cohorts. In cohort 1 of 675 patients, the average age of diagnosis for women with estrogen receptor (ER)-positive and ER-negative breast cancers was 53.2 and 48 years, respectively. In this cohort, homozygous variant (TT) carriers developed ER-negative carcinomas at an earlier age than homozygous wild-type (CC) or heterozygous (TC) such that the age at diagnosis was accelerated by 5.0 years (P = 0.018). This association was validated in a second cohort of breast cancer patients (n = 148), where TT carriers with ER-negative cancer developed the disease 3.8 years earlier than CC carriers (P = 0.006). The effect was more pronounced in Caucasians with ER-negative ductal carcinomas with TT homozygotes developing disease 7.5 years (P = 0.031) and 6.2 years (P = 7 x 10(-5)) earlier than CC carriers in cohorts 1 and 2, respectively. No association was seen in ER-positive ductal cancers suggesting that the SNP in MDM4 only has a functional association in ER-negative breast cancer.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/MDM4 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Nuclear Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Estrogen,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Suppressor Protein p53
|
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
1460-2180
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:volume |
30
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1910-5
|
pubmed:meshHeading |
pubmed-meshheading:19762336-Adult,
pubmed-meshheading:19762336-Age of Onset,
pubmed-meshheading:19762336-Breast Neoplasms,
pubmed-meshheading:19762336-Carcinoma, Ductal,
pubmed-meshheading:19762336-Cohort Studies,
pubmed-meshheading:19762336-Female,
pubmed-meshheading:19762336-Genetic Predisposition to Disease,
pubmed-meshheading:19762336-Humans,
pubmed-meshheading:19762336-Middle Aged,
pubmed-meshheading:19762336-Nuclear Proteins,
pubmed-meshheading:19762336-Polymorphism, Single Nucleotide,
pubmed-meshheading:19762336-Proto-Oncogene Proteins,
pubmed-meshheading:19762336-Receptors, Estrogen,
pubmed-meshheading:19762336-Tumor Suppressor Protein p53
|
pubmed:year |
2009
|
pubmed:articleTitle |
A polymorphic variant in human MDM4 associates with accelerated age of onset of estrogen receptor negative breast cancer.
|
pubmed:affiliation |
Department of Medicine-Division of Medical Oncology, The Cancer Institute of New Jersey, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, New Brunswick, NJ 08901, USA.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|